Clinical Trials
9 trialsNCT07567716 2026-05-05
Infiltration Pattern of Locally Advanced ESCC
Shanghai Chest Hospital
Enrolling by invitation
NCT07218003 2026-05-04
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Phase 1 Enrolling by invitation
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT07016737 2025-06-12
ESO-Nanjing12
Jiangsu Cancer Institute & Hospital
Phase 3 Enrolling by invitation
NCT06984055 2025-05-22
Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
Changhai Hospital
Enrolling by invitation
NCT06863831 2025-03-07
A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Enrolling by invitation
NCT06429865 2024-05-28
Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma
Changhai Hospital
Phase NA Enrolling by invitation
NCT06303583 2024-03-12
CRIS
Zhejiang Cancer Hospital
Phase 1/2 Enrolling by invitation
NCT06048926 2023-09-21
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Enrolling by invitation